Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 111,991

Document Document Title
WO/2016/078833A1
The invention relates to an improved method of preparing buprenorphine, a salt thereof, analogues of buprenorphine and their salts. In particular, the invention relates to a method of preparing buprenorphine and related products and salt...  
WO/2016/079736A3
Uses of agent which downregulate an activity or expression of a component participating in the mitochondrial apoptotic pathway are disclosed.  
WO/2016/078546A1
Disclosed are a low molecular weight polypeptide, nucleotide sequence encoding the polypeptide, and use of the polypeptide in preparing a drug for treating and preventing Alzheimer's disease (AD).  
WO/2016/081236A1
Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated within the biodegradab...  
WO/2016/079712A1
The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alon...  
WO/2016/081639A1
The invention provides antagonistic antibodies to BACl and methods of using the same for the treatment of neurological diseases and disorders.  
WO/2016/079709A1
The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alon...  
WO/2016/078587A1
The present invention relates to Lu AE58054 hydrochloride crystalline form A, and preparation method and application thereof, Lu AE58054 hydrochloride crystalline form A having a characteristic peak at a point where 2theta value is 17.1┬...  
WO/2016/079317A1
The present invention relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular the invention has found that inhibitors reducing FAS activity can be used for treatment of Par...  
WO/2016/081365A1
One aspect of the invention provides a method for treatment of a lysosomal storage disorder. The method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an age...  
WO/2016/078672A1
The present disclosure is directed to a method of treating stroke and/or symptoms associated with stroke by administration to a subject in need thereof a DN -TNF polypeptide that inhibits the activity of soluble TNF- but not transmembran...  
WO/2016/079710A1
The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alon...  
WO/2016/080516A1
The present invention provides a pharmaceutical composition containing cilnidipine or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention relates to: a dynamin-related protein 1 (Drp1) polymerization...  
WO/2016/081445A1
Provided herein are methods for treating epilepsy or seizure disorders comprising administering a composition to a subject, the composition comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated...  
WO/2016/081811A1
The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV...  
WO/2016/075137A1
The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of s...  
WO/2016/077724A1
A compound, or pharmaceutically acceptable salt thereof, having a formula (I) wherein R1 is H or optionally-substituted alkyl; R2 is optionally-substituted alkyl; R3 and R4 are each independently H or optionally-substituted alkyl; R5 is ...  
WO/2016/076761A1
´╗┐The invention (variants) relates to the field of medicine, pharmacology, biotechnology, molecular biology and genetic engineering, and may be used for analgesia. A proposed DNA plasmid for transient expression in mammalian cells, cons...  
WO/2016/074641A1
Use of reduced nicotinamide adenine dinucleotide (NADH) or salt thereof in preparing a drug or health care product for phenylketonuria treatment, a single dose of the NADH or salt thereof being 1-100 mg.  
WO/2016/075062A1
The present invention is directed to compounds according to Formula (I) which compounds are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses ...  
WO/2016/077654A1
Methods for treating, or reducing risk of developing, seasonal worsening of multiple sclerosis (MS) in a subject who has MS, comprising administering a melatonin agonist to a subject.  
WO/2016/074098A1
A method of promoting neural stem cell differentiation is provided comprising exposing neural stem cells to a dopamine D4 receptor antagonist.  
WO/2016/077840A3
This invention relates TfR-specific binding moieties with high specificity for and functional interaction with the transferrin receptor ("TfR"). These moieties may be used to carry biomolecules across membranes, including the blood brain...  
WO/2016/076507A1
The present invention relates to: a composition for reprogramming somatic cells into induced pluripotent stem cells, the composition containing a Reptin protein or a gene encoding the same; and a method for reprogramming somatic cells in...  
WO/2016/075516A1
The present invention describes the use of the Chinese medicinal compounds ginsenoside RB1, dihydromyricetin and salvianohc acid B, for use in diagnosing, monitoring and treating synucleinopathies, such as Parkinson's disease, in patients.  
WO/2016/075617A1
The invention relates to a fixed dose pharmaceutical formulation comprising analgesic agent and anti-spasmodic agent and one or more pharmaceutically acceptable excipients wherein the pharmaceutical formulation is used for relief of mens...  
WO/2016/075063A1
The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to ...  
WO/2016/074203A1
The present invention relates to a cell apoptosis inducer containing chlorine dioxide. The present invention relates to a cell apoptosis inducer kit containing the following two independent components: the first component: a chlorine dio...  
WO/2016/075181A1
The present invention provides spiro-thiazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The prese...  
WO/2016/077656A2
The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to...  
WO/2016/075457A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R 2 , R3, R4 and R5 are as defined in the specification for use in treating irritable bowe...  
WO/2016/074566A1
Disclosed are a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, an easily-hydrolytic prodrug ester thereof or an isomer thereof, and a pharmaceutical composition containing the compound used as a ...  
WO/2016/074336A1
An eaglewood sachet for baths. The eaglewood sachet is prepared through the following steps: washing 34-44 parts by weight of aquilaria sinensis, 24-34 parts by weight of incense tree and 24-34 parts by weight of agilawood, drying and mi...  
WO/2016/075330A1
The present invention relates to a novel class of compounds having the structure of formula (I) and pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. These compounds inhibit o...  
WO/2016/075064A1
The present invention is directed to compounds of Formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to ...  
WO/2016/077437A1
The present invention is directed to methods of preconditioning neurons to reduce neuronal inflammation in a subject. Such methods include a step of administering apoaequorin to a subject, wherein the subject's neurons are preconditioned...  
WO/2016/073895A1
The invention provides substituted pyrazolo[l,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gau...  
WO/2016/071211A1
The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pr...  
WO/2016/072599A1
The present invention relates to a pharmaceutical composition for treating autism spectrum disorders, containing clioquinol or a pharmaceutically acceptable salt thereof. In addition, the present invention relates to a food composition f...  
WO/2016/071283A1
Provided is a compound for use in medicine for inhibiting tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO), which compound comprises formula (I) wherein X1, X2, and X7, may be the same or different and each is in...  
WO/2016/072402A1
The present invention pertains to a compound having an exceptional effect for inhibiting retinoic-acid-receptor-related orphan receptors ╬│t, or a pharmacologically acceptable salt thereof. A compound represented by general formula (I) (...  
WO/2016/073716A1
The present disclosure relates in general to methods for the treatment of neurodegenerative disease, such as Huntington's Disease, using compositions comprising cysteamine or cystamine or salts or derivatives thereof.  
WO/2016/072871A1
The invention relates to the Proline-Rich Polypeptide complex (PRP) derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurotrophic Factor level a...  
WO/2016/073424A1
The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range ...  
WO/2016/071767A1
The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.  
WO/2016/073891A1
The invention provides substituted pyrrolo[l,2-a]pyrimi dines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Ga...  
WO/2016/071121A1
The present invention pertains to novel analgesics useful for treating pain. BLT2 agonists were found to desensitize TRPV1 mediated signalling in sensory neurons. Thus the invention provides BLT2 agonists as novel pain therapeutics. Addi...  
WO/2016/070817A1
The present invention relates to the field of pharmaceutical engineering, and in particular relates to use of edaravone in preparing drugs for preventing and treating cerebral amyloid angiopathy (CAA). By administrating edaravone, the pr...  
WO/2016/072842A1
The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a product for treating, preventing or reducing the risk of occurrence of behavioral ...  
WO/2016/073693A3
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.  

Matches 251 - 300 out of 111,991